Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of modified-release dexamfetamine [HLD 100] in attention-deficit hyperactivity disorder

Next Previous
X
Search
Trial Profile

Phase III trial of modified-release dexamfetamine [HLD 100] in attention-deficit hyperactivity disorder

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 28 Jun 2013 New trial record
    • 25 Jun 2013 This trial is anticipated to start in the first quarter of 2014, and its trial design will be dependent on the outcomes of the phase II trial, according to a Highland Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top